Advertisement

Disproportional increase in psoriasis reports in association with B cell depleting therapies in patients with multiple sclerosis

      Highlights

      • Multiple sclerosis (MS) and psoriasis share several immunopathogenic pathways
      • The FDA adverse event reporting system is a resource for pharmacovigilance studies
      • Highest reports of psoriasis in MS patients treated with B cell depleting therapy
      • Higher reports of psoriasis in female MS patients compared to males

      Abstract

      Background

      Some pathways involved in the pathogenesis of psoriasis share similarities with processes involved in multiple sclerosis (MS) pathogenesis. However, the association between MS and psoriasis is poorly understood. Since disease-modifying therapies for MS have various targets, it may be possible that the occurrence of psoriasis varies by drug.

      Objective

      To analyze the frequency of psoriasis reports in patients treated with various disease-modifying therapies for MS.

      Methods

      Data was collected using the FDA Adverse Event Reporting System (FAERS) and OpenFDA database between January 2009 and June 2020. The study analyzed total reports of psoriasis out of total reports in the “Skin and Subcutaneous Tissue Disorders” category for each drug and explored age, sex distribution, and report source. OpenFDA data was used to perform statistical analyses including reporting odds ratios (ROR) and information components.

      Results

      The study identified 517 psoriasis reports of 45,547 total skin and subcutaneous tissue disorders (1.13%) in FAERS. The highest proportions of reports in this study were associated with rituximab, ocrelizumab, and interferon beta 1a. The lowest proportion of reports were associated with glatiramer acetate, alemtuzumab, dimethyl fumarate and teriflunomide. Reports of other autoimmune skin disorders were minimal (29 vitiligo, 33 pemphigoid, and 7 pemphigus). Patients primarily drove reports for most DMTs versus healthcare providers. The proportion of reports from female patients were the highest for each DMT except alemtuzumab. OpenFDA query retrieved 302 total reports of psoriasis. Significantly increased reporting odds ratios (RORs, 95% confidence interval) of psoriasis were noted for rituximab (7.14, 3.92-13.00), ocrelizumab (3.79, 2.74-5.23), and fingolimod (1.33, 1.01-1.76). Significantly decreased RORs were noted for natalizumab (0.53, 0.36-0.80), glatiramer acetate (0.58, 0.35-0.96), and dimethyl fumarate (0.71, 0.53-0.94).

      Conclusion

      There are frequent reports of psoriasis in MS patients treated with various DMTs. However, reports and RORs were disproportionally high in association with B cell depleting therapies. Further research is required to determine if certain DMTs may serve as better options for individuals affected by, or at high-risk for developing psoriasis.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Amschler K
        • Meyersburg D
        • Kitze B
        • Schön MP
        • Mössner R.
        Onset of psoriasis upon interferon beta treatment in a multiple sclerosis patient.
        Eur J Dermatology. 2016; 26: 211-212https://doi.org/10.1684/ejd.2015.2602
        • Arslan D
        • Aksakal AB
        • Erdem Ö
        • Tuncer MA.
        A case of drug-induced bullous pemphigoid associated with teriflunomide: A patient with relapsing multiple sclerosis.
        Mult Scler Relat Disord. 2020; : 43https://doi.org/10.1016/j.msard.2020.102157
        • Aslam A
        • Marsland AM
        • Rog D
        • Griffiths CEM.
        Alemtuzumab and chronic plaque psoriasis.
        Br. J. Dermatol. 2013; 169: 184-186https://doi.org/10.1111/bjd.12226
        • Bar-Or A
        • Pachner A
        • Menguy-Vacheron F
        • Kaplan J
        • Wiendl H.
        Teriflunomide and its mechanism of action in multiple sclerosis.
        Drugs. 2014; 74: 659-674https://doi.org/10.1007/s40265-014-0212-x
        • Bate A
        • Evans SJW.
        Quantitative signal detection using spontaneous ADR reporting.
        Pharmacoepidemiol Drug Saf. 2009; 18: 427-436https://doi.org/10.1002/PDS.1742
        • Bomze D
        • Hasan Ali O
        • Bate A
        • Flatz L.
        Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden.
        JAMA Oncol. 2019; 5: 1633-1635https://doi.org/10.1001/JAMAONCOL.2019.3221
        • Brück J
        • Dringen R
        • Amasuno A
        • Pau-Charles I
        • Ghoreschi K.
        A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis.
        Exp. Dermatol. 2018; 27: 611-624https://doi.org/10.1111/exd.13548
        • Chun J
        • Hartung HP.
        Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
        Clin. Neuropharmacol. 2010; 33: 91-101https://doi.org/10.1097/WNF.0b013e3181cbf825
        • Cotchett KR
        • Dittel BN
        • Obeidat AZ.
        Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis.
        Mult Scler Relat Disord. 2021; (Published online)https://doi.org/10.1016/j.msard.2021.102787
        • Darwin E
        • Romanelli P
        • Lev-Tov H
        • Author C.
        Ocrelizumab-Induced Psoriasiform Dermatitis in a.
        Patient with Multiple Sclerosis. 2018; 24
        • Diebold M
        • Müller S
        • Derfuss T
        • Décard BF.
        A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions.
        Mult Scler Relat Disord. 2019; 31: 38-40https://doi.org/10.1016/j.msard.2019.03.009
        • Egeberg A
        • Mallbris L
        • Gislason GH
        • Skov L
        • Hansen PR.
        Risk of multiple sclerosis in patients with psoriasis: A Danish nationwide cohort study.
        J. Invest. Dermatol. 2016; 136: 93-98https://doi.org/10.1038/JID.2015.350
      1. Geils HM, Katz JD, Lathi ES, Stribling IC. Psoriasis Flare during Ocrelizumab Therapy for Relapsing Multiple Sclerosis: Report of 2 Cases. Published online May 2019.

        • Göbel K
        • Ruck T
        • Meuth SG.
        Cytokine signaling in multiple sclerosis: Lost in translation.
        Mult Scler J. 2018; 24: 432-439https://doi.org/10.1177/1352458518763094
        • Herzinger T
        • Kleuser B
        • Schäfer-Korting M
        • Korting HC.
        Sphingosine-1-phosphate signaling and the skin.
        Am. J. Clin. Dermatol. 2007; 8: 329-336https://doi.org/10.2165/00128071-200708060-00002
        • Hilger C
        • Riedhammer C
        • Orsó E
        • Weissert R.
        Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses.
        Front. Immunol. 2020; 11https://doi.org/10.3389/fimmu.2020.563645
        • Karthikeayan V
        • Whittam D
        • Copeland Y
        • Huda S
        • Jacob A.
        181 Multiple Sclerosis associated with Psoriasis – is alemtuzumab the drug of choice?.
        J. Neurol. Neurosurg. Psychiatry. 2019; 90 (-e48): e48https://doi.org/10.1136/JNNP-2019-ABN-2.161
        • Kwok T
        • Loo WJ
        • Guenther L.
        Psoriasis and multiple sclerosis: Is there a link?.
        J. Cutan. Med. Surg. 2010; 14: 151-155https://doi.org/10.2310/7750.2010.09063
        • La Mantia L
        • Capsoni F
        Psoriasis during interferon beta treatment for multiple sclerosis.
        Neurol Sci. 2010; 31: 337-339https://doi.org/10.1007/s10072-009-0184-x
        • Lambrianides S
        • Kinnis E
        • Leonidou E
        • Pantzaris M.
        Does Natalizumab Induce or Aggravate Psoriasis? A Case Study and Review of the Literature.
        Case Rep Neurol. 2018; 10: 286-291https://doi.org/10.1159/000492891
        • Loma I
        • Heyman R.
        Multiple Sclerosis: Pathogenesis and Treatment.
        Curr. Neuropharmacol. 2011; 9: 409-416https://doi.org/10.2174/157015911796557911
        • Maarouf A
        • Rico A
        • Boutiere C
        • et al.
        Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?.
        Neurol Neuroimmunol neuroinflammation. 2020; 7: 825https://doi.org/10.1212/NXI.0000000000000825
        • Millán-Pascual J
        • Turpín-Fenoll L
        • Del Saz-Saucedo P
        • Rueda-Medina I
        • Navarro-Muñoz S.
        Psoriasis during natalizumab treatment for multiple sclerosis.
        J. Neurol. 2012; 259: 2758-2760https://doi.org/10.1007/s00415-012-6713-1
        • Negrotto L
        • Correale J.
        Palmar pustular psoriasis associated with teriflunomide treatment.
        Mult Scler Relat Disord. 2019; 27: 400-402https://doi.org/10.1016/j.msard.2018.11.020
        • Nourbakhsh B
        • Mowry EM.
        Multiple sclerosis risk factors and pathogenesis.
        Contin Lifelong Learn Neurol. 2019; (Published online)https://doi.org/10.1212/CON.0000000000000725
        • Park G
        • Jung H
        • Heo SJ
        • Jung I.
        Comparison of Data Mining Methods for the Signal Detection of Adverse Drug Events with a Hierarchical Structure in Postmarketing Surveillance.
        Life. 2020; 10: 1-22https://doi.org/10.3390/LIFE10080138
        • Peñas PF
        • Gómez M
        • Buezo GF
        • et al.
        Differential expression of activation epitopes of β1 integrins in psoriasis and normal skin.
        J. Invest. Dermatol. 1998; 111: 19-24https://doi.org/10.1046/j.1523-1747.1998.00232.x
        • Rao SP
        • Sancho J
        • Campos-Rivera J
        • et al.
        Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.
        PLoS One. 2012; 7https://doi.org/10.1371/journal.pone.0039416
        • Reszke R
        • Szepietowski JC.
        A safety evaluation of dimethyl fumarate in moderate-to-severe psoriasis.
        Expert Opin. Drug Saf. 2020; (Published online)https://doi.org/10.1080/14740338.2020.1736553
        • Schaper K
        • Dickhaut J
        • Japtok L
        • et al.
        Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis.
        J. Dermatol. Sci. 2013; 71: 29-36https://doi.org/10.1016/j.jdermsci.2013.03.006
        • Silfvast-Kaiser AS
        • Homan KB
        • Mansouri B.
        <p>A narrative review of psoriasis and multiple sclerosis: links and risks</p>.
        Psoriasis Targets Ther. 2019; 9: 81-90https://doi.org/10.2147/ptt.s186637
        • Sulaimani J
        • Cluxton D
        • Clowry J
        • et al.
        Dimethyl fumarate modulates the Treg–Th17 cell axis in patients with psoriasis.
        Br. J. Dermatol. 2020; (Published online)https://doi.org/10.1111/bjd.19229
        • Toussirot É
        • Béreau M
        • Bossert M
        • Malkoun I
        • Lohse A.
        Occurrence of Psoriatic Arthritis during Interferon Beta 1a Treatment for Multiple Sclerosis.
        Case Rep Rheumatol. 2014; 2014: 1-3https://doi.org/10.1155/2014/949317
        • Weber MS
        • Hohlfeld R
        • Zamvil SS.
        Mechanism of Action of Glatiramer Acetate in Treatment of Multiple Sclerosis. 2022;
        • Yaldizli O
        • Putzki N.
        Natalizumab in the treatment of multiple sclerosis.
        Ther Adv Neurol Disord. 2009; 2: 115-128https://doi.org/10.1177/1756285608101861
        • Zhang LJ.
        Type1 interferons potential initiating factors linking skin wounds with psoriasis pathogenesis.
        Front. Immunol. 2019; (Published online)https://doi.org/10.3389/fimmu.2019.01440